Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Virpax Pharmaceuticals Inc (NQ: VRPX )

0.7598 -1.5302 (-66.82%)
Streaming Delayed Price Updated: 3:07 PM EDT, May 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Virpax Pharmaceuticals Inc

< Previous 1 2 3 Next >
Virpax Pharmaceuticals Engages Dr. Pardeep Gupta to Assist in Development of Company’s Lead Asset, Probudur™
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Reports on Progress of Envelta™
From Virpax Pharmaceuticals
Via Business Wire
Virpax Pharmaceuticals Announces Appointment of Barbara A. Ruskin, Ph.D, J.D. to the Board of Directors
From Virpax Pharmaceuticals
Via Business Wire
Virpax Pharmaceuticals Reports 2022 Year-End Results
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Announces Positive Preclinical Toxicology Results in Support of Molecular Envelope Technology (MET)
From Virpax Pharmaceuticals
Via Business Wire
Virpax Pharmaceuticals Engages New England Investors to Direct Licensing Strategy for Envelta™ in China
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals to Utilize Dr. Neil K. Singla to Assist in Development of Probudur™
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals Engages Destum Partners to Direct Strategic Global Partnering Efforts
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals Engages Dr. Kenneth W. Sommerville and Dr. Lawrence Fried to Assist in Development of NobrXiol™ (formerly VRP324)
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals Reports on FDA Pre-IND Response for NobrXiol™ (formerly VRP324)
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals Reports 2022 Third Quarter Results
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Dr. Jeffrey Gudin, Chief Medical Officer of Virpax Pharmaceuticals, to Present Poster at World Congress of World Institute of Pain
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals Reports 2022 Second Quarter Results and Recent Developments
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pursues OTC Medical Device Pathway for AnQlar™
From Virpax Pharmaceuticals
Via Business Wire
Virpax Will Pursue Direct to OTC Pathway for Epoladerm™ for Pain Associated with Osteoarthritis
From Virpax Pharmaceuticals
Via Business Wire
Virpax Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals Reports 2022 First Quarter Results and Recent Developments
From Virpax® Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals Enters Into CRADA With The U.S. Army Institute of Surgical Research
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Successfully Completes Initial Preclinical Studies for VRP324
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals Reports 2021 Year-End Results
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Completes All FDA-Required Pre-Clinical Studies for Epoladerm™
From Virpax® Pharmaceuticals, Inc.
Via Business Wire
Nanomerics Receives Further Upfront Payment for Anti-Viral Spray AnQlar(TM)
LONDON, UK / ACCESSWIRE / March 22, 2022 / Nanomerics Ltd., a private speciality pharmaceutical company, today announced the receipt of a further milestone payment on agreeing the expansion of its... 
From Nanomerics Ltd
Via AccessWire
Virpax Pharmaceuticals Expands AnQlar™ Development and Commercialization Rights Through Worldwide Licensing Agreement
From Virpax Pharmaceuticals, Inc.
Via Business Wire
News Outlets Highlight Virpax Pharmaceuticals and Its Potential Solutions for the Opioid Crisis and COVID-19
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Reports Favorable Preclinical Safety Data for Envelta™  for the Treatment of Acute and Chronic Pain
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Altasciences Chosen by Virpax Pharmaceuticals, Inc. to Conduct First-in-Human Study of Epoladerm™ for Chronic Pain Associated with Osteoarthritis of the Knee
From Altasciences and Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax® Successfully Completes Preclinical Dermal Safety Studies for Epoladerm™
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax® Pharmaceuticals to Present at H.C. Wainwright BioConnect Virtual Conference
From Virpax® Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals Recaps Milestones and Highlights Product Portfolio
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Announces Clinical Trial Site in Canada for First in Human Study of Epoladerm™ for Pain Associated with Osteoarthritis of the Knee
From Virpax Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.